Use of Palliative Radiotherapy Among Patients With Metastatic Non-small-cell Lung Cancer in Puerto Rico

Valerie Quinones-Avila (✉ valerie.quinones@upr.edu)

University of Puerto Rico, Medical Sciences Campus

Karen J. Ortiz-Ortiz

Puerto Rico Central Cancer Registry

Ruth Ríos-Motta

University of Puerto Rico, Medical Sciences Campus

Heriberto Marín-Centeno

University of Puerto Rico, Medical Sciences Campus

Guillermo Tortolero-Luna

Puerto Rico Central Cancer Registry

Research Article

Keywords: use of palliative radiotherapy, non-small cell lung cancer, Puerto Rico

Posted Date: February 26th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-253381/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Palliative Care on August 13th, 2021.

See the published version at <https://doi.org/10.1186/s12904-021-00819-x>.

Abstract

Background: Palliative radiotherapy (RT) represents an important treatment opportunity for improving the quality of life in metastatic non-small cell lung cancer (NSCLC) patients through the management of symptoms within the course of the illness. This study examines the patient and clinical factors associated with palliative RT use among metastatic NSCLC patients in Puerto Rico.

Methods: A retrospective cohort study was performed using secondary data analysis from 2009-2015 from the Puerto Rico Central Cancer Registry–Health Insurance Linkage Database (PRCCR-HILD). A logistic regression model was used to examine factors associated with palliative RT.

Results: Among the 929 patients identified with metastatic NSCLC, 33.80% received palliative RT within the first year after diagnosis. After adjusting for other covariates, receipt of chemotherapy ($OR_{Adj} = 3.90$; 95% CI = 2.91-5.45; $P < 0.001$) and presence of symptoms ($OR_{Adj} = 1.41$; 95% CI = 1.00-1.98; $P = 0.045$) were associated with increased odds of palliative RT use. Although marginally significant, patients with private health insurance had increased odds of palliative RT use ($OR_{Adj} = 1.50$; 95% CI = 0.98-2.29; $P = 0.061$) when compared to beneficiaries of Medicaid, after adjusting by other covariates.

Conclusions: The results of this study reveal concerning underuse of palliative RT among patients with metastatic NSCLC in Puerto Rico. Additional research is necessary to further understand the barriers to using palliative RT on the island.

Background

Lung cancer is the third most common cancer among males and the fifth most common cancer among females in the Commonwealth of Puerto Rico, an unincorporated territory of the United States [1]. It also ranked as the third leading cause of cancer mortality in both men and women in the island [1]. Although lung cancer incidence and mortality rates are lower in Puerto Rico than in the United States, it remains as significant public health problem. Since most lung cancer patients are diagnosed at an advanced stage of the disease, these patients experience more signs of symptom distress than patients diagnosed with other types of cancer [2]. Symptoms such as pain are frequently followed by the worsening of other symptoms and may affect quality of life [3].

The relief and management of symptoms in lung cancer patients is frequently achieved through the early integration of palliative radiation therapy (RT), particularly for patients with advanced or metastatic non-small cell lung cancer (NSCLC) [3–5]. Palliative RT is used to ultimately improve the quality of life for these patients by treating focal symptoms arising from the primary or metastatic tumor [5], restoring function, preventing the progression of the disease in the treated area or relieving suffering [6]. However, despite the potential benefits of palliative RT, significant variability exists in the integration of this treatment into the healthcare delivery for NSCLC patients worldwide [7]. Variations in treatment may result in worse health outcomes, higher social costs and reduced cost-effectiveness [8].

In Puerto Rico, little is known about the use of palliative care services, such as palliative RT, for NSCLC patients. Also, the lack of training, protocols, and palliative care teams and specialists [9] may exacerbate the gap between the need for palliative care services and availability of these services in the island. This is of great concern because lack of appropriate and timely use of oncologic health services may contribute to the observed differences in cancer-related health outcomes and survival [7,10]. Therefore, understanding the barriers to standards of care is essential for addressing the disparities in the burden associated with symptom distress experienced by the NSCLC population, which can ultimately result in a low quality of life for these patients [11]. As such, this study aims to characterize the use of palliative RT among metastatic NSCLC patients in Puerto Rico. Information about the utilization profile of palliative RT care in Puerto Rico will help identify barriers to comprehensive oncologic patient care and allow for the development of health interventions to improve care delivery.

Methods

Data Source

The source of information for this study was the Puerto Rico Central Cancer Registry-Health Insurance Linkage Database (PRCCR-HILD). As one of the main surveillance systems in the island, the PRCCR monitors all cancer diagnoses obtained from health facilities in Puerto Rico that diagnose and treat cancer patients, such as hospitals, outpatient clinics, pathology laboratories and RT/chemotherapy sites. Demographic characteristics, date of cancer diagnosis, anatomic cancer site, histology type, method of diagnosis, stage of disease at diagnosis, therapy and follow-up status, and cause of death are included in the type of information collected. Data in the PRCCR files are linked to the insurance claims files from Medicare, Medicaid and private insurers in order to constitute the PRCCR-HILD. The process of linking claims from the health insurance databases is performed using a deterministic match similar to the one used by SEER-Medicare [12]. All data is de-identified so that the health information is not linked to individual patients.

The PRCCR has been part of the United States National Program of Cancer Registries (NPCR) since 1997. The Surveillance, Epidemiology, and End Results (SEER) Program and the North American Association of Central Cancer Registries (NAACCR) standards are used for coding data. In the most recent NPCR audit, the PRCCR complied with all the criteria, including the completeness of case ascertainment (>99.0%), comparable to the United States median (99.95%) [13].

Study Cohort

This study included patients aged 21 years or older in the PRCCR-HILD with a primary diagnosis and histologic confirmation of metastatic NSCLC (defined as stage III-B with malignant effusion (wet IIIB) or stage IV NSCLC [14] between January 2009 and December 2015. Only residents of Puerto Rico at diagnosis were included. NSCLC was required to be pathologically confirmed and diagnosed prior to death as the primary cancer diagnosis. To ensure we had adequate claims information for our analyses,

patients with incomplete claims data regarding cancer diagnosis (cancer type and cancer stage), with multiple primary diagnoses, with missing diagnosis date, without claims data after the primary diagnosis, without enrollment data during the first year after diagnosis, or with a death certificate within 15 days from diagnosis were excluded (Figure 1).

Study Variables

The variables of interest for this study were identified via data in the PRCCR-HILD as well as insurance claims codes for the Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and the International Classification of Diseases for Oncology 3th (ICD-O-3). The patient's diagnosis was identified using the ICD-O-3 codes for metastatic NSCLC site codes C340-C349, excluding small cell lung cancer (histology codes: 80413, 80423, 80433, 80443, and 80453), lymphomas, and sarcomas.

Our primary outcome variable, use of palliative RT, was defined by a combination of patient cohort (metastatic NSCLC primary diagnosis) and patient claims using HCPCS, CPT, and ICD codes for radiation courses occurring within one year of diagnosis. Codes used for identifying receipt of palliative RT included stereotactic RT, conventional radiation treatment deliver, conventional IMRT delivery, high-energy neutron radiation, and proton treatment delivery. Previous work with surveillance registry has also considered that the RT for patients with advanced NSCLC is being provided with palliative intent as a standard of care [15].

The independent variables were categorized in order to assess for nonlinear trends. Demographic variables included age, sex, and marital status. Health services variables included health insurance type, density of RT centers, and geographic location. Density of RT centers was defined as the proportion of RT center per region of patient residency, as defined by Health Department Coalitions by Health Region [16,17]. This variable was categorized according to the distribution of the study sample: low (0-2 centers), medium (3-6 centers), high (≥ 7 centers). Geographic location referred to whether or not the patient's municipality of residency belonged to a metropolitan area, as defined by the Office of Management and Budget (OMB) [18,19]. Clinical variables included surgery, chemotherapy, year of diagnosis (2009-2015), symptoms and comorbidity. Surgery and chemotherapy receipt were identified at any time within one year of diagnosis. Common pain symptoms due to cancer or its treatment were identified in the claims data and included at least one of the following: malaise and fatigue, generalized pain, dyspnea and respiratory abnormalities, dysphagia, acute pain, cough, hemoptysis, chest pain, brachial plexopathy, or superior cava syndrome. Comorbidity was assessed during one year prior diagnosis using the modified Charlson's comorbidity index described by Klabunde et al. [20,21].

Statistics

First, descriptive statistics were used to examine the characteristics of the study population. Then, prevalence measures were used to determine the palliative RT use among the study participants. Univariate associations with palliative RT were determined with two-tailed Pearson chi-squared tests.

Univariate logistic regression models were performed in order to determine the unadjusted magnitude of the associations. Then, all covariates, regardless their statistical significance in the univariate models, were included in a multivariate logistic regression model to assess covariates independently associated with the use of palliative RT. Exploratory analysis was conducted to identify interactions between the independent variables. These would be accounted for in the multivariate model if considered appropriate. Statistical significance was set at the $P = 0.05$ level. Results were presented as odds ratio (OR) with 95% confidence intervals and P values. Statistical analyses were performed using STATA software (Stata Corp., LP. College Station, TX).

Results

Patient characteristics for the 929 study participants are presented in Table 1. The age of the study patients ranged from 28 to 96 years old. The median age was 67. The majority of the patients consisted of males (59.42%) in the 60-74 age category (48.65%), married (54.68%), and with Medicaid as the primary payer (31.22%). A vast majority resided in a Metro region (96.23%), and more than half of the regions had a medium density of RT centers (65.12%). Although most patients did not receive surgery (91.17%), almost half of the patients received chemotherapy (47.47%). Finally, although the majority (66.52%) had no comorbidities, 65.66% experienced pain.

Overall, 33.80% of the study participants received palliative RT within one year of diagnosis. Table 1 also lists the distribution of palliative RT use and non-use by patient characteristics. In the bivariate analysis, associations with palliative RT use were seen with age, health insurance, receiving chemotherapy, and symptoms ($p < 0.05$). The use of palliative RT decreased with increasing age categories (39.92% for ages 28-59; 33.63% for ages 60-74, and 26.94% for ages 75+; $P = 0.011$). Meanwhile, it was higher in patients with private health insurance (44.61% vs 28.28%, 38.31%, 27.35%, respectively; $P < 0.001$); patients receiving chemotherapy (50.57% vs 18.65%; $P < 0.001$); and patients experiencing pain symptoms (38.36% vs 25.08%; $P < 0.001$) when compared to their respective counterparts.

Results for the univariate logistic regressions were consistent with the Pearson Chi-Squared results (Table 2). Potential interactions between health insurance and covariates were also evaluated. However, the terms of interaction were not statistically significant ($P = 0.3280$). Therefore, all the covariates, regardless of their statistical significance, were included in a multivariate logistic regression model to identify covariates independently associated with the use of palliative RT (Table 2). Although age lost its significance, private health insurance remained marginally significant, and both chemotherapy treatment and symptomatology remained statistically significant, after adjusting for other covariates. In the adjusted model, patients treated with chemotherapy were nearly four times more likely to receive palliative RT than their counterparts (OR = 3.90; 95% CI: 2.91, 5.45; $P < 0.0001$). Furthermore, patients with pain symptoms were 41% more likely to receive palliative RT than patients without pain symptoms (OR = 1.41; 95% CI: 1.00, 1.98; $P = 0.045$), after adjusting for other covariates. Finally, patients with private health insurance were 50% more likely to receive palliative RT than patients with Medicaid (OR=1.50, 95% CI: 0.98-2.29; $P = 0.061$).

Discussion

Our findings suggest a lower use of palliative RT among patients with metastatic NSCLC in Puerto Rico (33.80%) compared to patients in the United States (50% or greater) in prior studies [22–25]. The low rate of palliative RT in Puerto Rico is concerning, given the value of this treatment in improving the quality of life in advanced NSCLC. The available services might be failing to refer palliative treatment or patients might be refusing treatment due to stigma, unawareness, lack of staff, or even more robust clinical guidelines. Training and protocol inadequacies, decreased comfort level, and decreased access to teams and experts in palliative care [26] exacerbate the gap between the need for palliative care services and availability and usage of these services in the island. This is of great concern because a more detailed picture of palliative care that currently exists in cancer centers in Puerto Rico can help identify deficiencies and barriers to comprehensive cancer care and allow development of health interventions to improve care delivery.

Our data also shows differences in palliative RT by demographic and health service, and clinical characteristics. Receipt of chemotherapy was associated with increased odds of palliative RT use among NSCLC patients ($OR_{Adj} = 3.9$; 95% CI = 2.91-5.45; $P < 0.001$), after adjusting for other covariates. Meanwhile, decreased odds of palliative RT use was associated with increasing age categories in the unadjusted model ($OR = 0.55$ 95% CI: 0.3-0.82; $P = 0.003$), but lost its significance after adjusting for other covariates ($OR = 0.71$, 95% CI: 0.44-1.17; $P = 0.182$). These findings support prior work considering receipt of chemotherapy and younger age at diagnosis as proxies for higher performance status of patients who may withstand the rigors of more intensive treatment, such as palliative RT [14,22,27,28]. Also, an age disparity with palliative RT use has been consistently found among older patients with advanced cancer [14,22,23,29], suggesting a gap between quality of cancer care and the needs of a population that might benefit from it. Reasons for this disparity could potentially include higher comorbidity, shorter survival, less disposition, and lack of transportation to receive more intensive cancer care among the elderly, which could impact both the patient's and doctor's decision to use palliative RT [29].

Moreover, in this study, patients with pain symptoms were 41% more likely to receive palliative RT than patients without pain symptoms, after adjusting for other covariates ($OR_{Adj} = 1.41$; 95% CI = 1.00-1.98; $P = 0.045$). However, the majority of patients experiencing symptoms (64.64%) did not end up receiving palliative RT. Perhaps the findings from this study might indicate a disparity in access to palliative RT among patients with symptomology due perhaps to patient refusal of treatment [24]. Previous studies have included symptomology as a covariate for measuring effectiveness of palliative RT [30,31], rather than as a predictor for palliative RT use.

Although marginally significant, after adjusting for other covariates, patients with private health insurance were 50% more likely to receive palliative RT than patients on the Government Health Plan. One reason for this disparity, well known in literature, is that lower socioeconomic status could affect a patient's ability to pay deductibles or copayments, which could affect his or her willingness to receive

palliative RT [23]. Another reason for this difference may be that patients with a lower socioeconomic status have less access to transportation, which could also limit their access to the radiation center [23,32]. Lastly, it has been observed that palliative RT can differ according to the reimbursement structure [22]. For Puerto Rico, this indicates that a change of the financial incentives for palliative RT care may be required because reimbursement-related financial incentives may be promoting the under-reporting of palliative RT care in the island (33.80%), which could lead to biased assessments of the utilization and expenditure of care.

There are several limitations in this study. For example, we could not assess important information on how the palliative RT was delivered, such as site of radiation, number of fractions, physician intent, and physician preferences, because the PRCCR-HILD does not collect such information. Also, mortality might have affected the study's internal validity because participants may have died during the period of interest for this study, due to the metastatic stage of our study population. To address this source of bias, we excluded those patients that died within 15 days of diagnosis (n=64). Finally, this study may be potentially relevant only to the cancer community in Puerto Rico and not necessarily generalizable to other communities in the United States or elsewhere.

Conclusion

Our findings have implications for the oncologic care of patients with NSCLC in Puerto Rico. The disparities in use of palliative RT found among elderly patients and beneficiaries in Medicaid suggest a call to action for further work on addressing the underlying causes and creating interventions or reimbursement structures for these populations that might benefit from the treatment. The identified disparities in chemotherapy use implies the need to further understand how palliative RT is delivered in conjunction with chemotherapy in Puerto Rico, and the development of updated guidelines to address the clinical implications. Finally, disparities in symptomatology imply that although the presence of symptoms is a facilitator for palliative RT use, early integration of palliative RT is key to effectively manage those symptoms.

List Of Abbreviations

CDC: Centers of Disease Control

CI: confidence interval

CPT: Current Procedural Terminology

HCPCS: Healthcare Common Procedure Coding System

ICD-O: International Classification of Diseases for Oncology

NAACCR: North American Association of Central Cancer Registries

NPCR: National Program of Cancer Registries

NSCLC: non-small cell lung cancer

OR: Odds Ratio

OR_{Adj}: Odds Ratio (Adjusted)

PR: Puerto Rico

PRCCR-HILD: Puerto Rico Central Cancer Registry–Health Insurance Linkage Database

PRCCR: Puerto Rico Central Cancer Registry

PRCCR-HILD: Puerto Rico Central Cancer Registry–Health Insurance Linkage Database

RT: Radiotherapy

SEER : Surveillance, Epidemiology, and End Results

Declarations

Ethics Statement.

The study was reviewed and approved by the Institutional Review Board of the University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico (Protocol Number B0810120). The study involved a secondary data-analysis of the databases of the Puerto Rico Central Cancer Registry (PRCCR). Patient confidentiality was maintained, as all registry and linked claims data was de-identified.

Consent for publication.

Not applicable

Availability of data and materials.

The data that support the findings of this study are available from PRCCR but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of PRCCR.

Competing interests.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Funding.

This study was funded by a federal grant from the Puerto Rico NCI Community Oncology Research Program Minority/Underserved-Cancer Care Delivery Research (Award Number 5UG1CA189862) and by the National Program of Cancer Registries (NPCR) of the Centers of Disease Control and Prevention (CDC)- (Award Number: NU58DP006318) to the Puerto Rico Central Cancer Registry (PRCCR)

Authors' contributions.

Valerie Quinones Avila: Conceptualization and design, Data analysis and interpretation, Manuscript writing-original draft preparation. **Karen J Ortiz-Ortiz:** Conceptualization and design, Manuscript writing-review & editing, Data gathering. **Ruth Ríos-Motta:** Writing-Review & Editing. **Heriberto Marín-Centeno:** Writing-Review & Editing. **Guillermo Tortolero-Luna:** Writing-Review & Editing.

Acknowledgements.

Not applicable.

References

1. Coalition PRCC. Puerto Rico Comprehensive. In: *Puerto Rico Comprehensive Cancer Control Plan: 2015-2020.* ; 2014.
2. Cooley ME. Symptoms in adults with lung cancer. A systematic research review. *J Pain Symptom Manag.* 2000;19(2):137-153. [https://doi.org/10.1016/S0885-3924\(99\)00150-5](https://doi.org/10.1016/S0885-3924(99)00150-5).
3. Simmons CPL, MacLeod N, Laird BJA. Clinical management of pain in advanced lung cancer. *Clin Med Insights Oncol.* 2012;6:331-346. doi:10.4137/CMO.S8360
4. Putora PM, Früh M, Kern L. The place of radiotherapy in the palliative management of NSCLC. *Breathe.* 2011;8(2):135-143. doi:10.1183/20734735.012711
5. Spencer K, Parrish R, Barton R, Henry A. Palliative radiotherapy. *BMJ.* 2018;360. doi:10.1136/bmj.k821
6. Sejpal S V, Bhate A, Small W. Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastases. *Semin Intervent Radiol.* 2007;24(4):363-374. doi:10.1055/s-2007-992324
7. IAEA. *IAEA Human Health Series Reports No. 2: Radiotherapy in Palliative Care: Development and Implementation.*; 2012. <http://www.iaea.org/Publications/index.html>.
8. Tovar I, Expósito J, Jaén J, et al. Pattern of use of radiotherapy for lung cancer: A descriptive study. *BMC Cancer.* 2014;14(1). doi:10.1186/1471-2407-14-697
9. Rosado Rivera M, Soto Torres F. Physician Attitudes on the Provision of Palliative Care in Puerto Rican Emergency Departments. *J Palliat Care Med.* 2014;05(01):1-5. doi:10.4172/2165-7386.1000i201
10. Chance WW, Ortiz-Ortiz KJ, Liao K-P, et al. Underuse of Radiation Therapy After Breast Conservation Surgery in Puerto Rico: A Puerto Rico Central Cancer Registry–Health Insurance Linkage Database

- Study. *J Glob Oncol*. 2018;(4):1-9. doi:10.1200/jgo.2016.008664
11. Simone CB, Jones JA. Palliative care for patients with locally advanced and metastatic non-small cell lung cancer. *Ann Palliat Med*. 2013;2(4):178-17888. doi:10.3978/j.issn.2224-5820.2013.08.02
 12. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. *Med Care*. 1993;31(8):732-748.
 13. Centers for Disease Control and Prevention. *Data Evaluation Reports, Puerto Rico- Diagnosis Years 1995-2017*; 2019.
 14. Lam MB, Li L, Cronin A, Schrag D, Chen AB. Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer. *Adv Radiat Oncol*. 2018;3(3):382-390. doi:10.1016/j.adro.2018.04.005
 15. Kress MAS, Jensen RE, Tsai HT, Lobo T, Satinsky A, Potosky AL. Radiation therapy at the end of life: A population-based study examining palliative treatment intensity. *Radiat Oncol*. 2015;10(1). doi:10.1186/s13014-014-0305-4
 16. pr.gov. Puerto Rico Healthcare Coalition. <http://www.salud.gov.pr/Profesionales-y-Proveedores/Pages/Proveedores/Coaliciones-de-Servicios-de-Salud.aspx#hccregiones>. Published 2019.
 17. World Health Organization. Density of radiotherapy units (per million population). <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/2441>. Published 2020.
 18. Agriculture UD of. Rural-Urban Continuum Codes. 2020. <https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/>.
 19. US Census Bureau. Metropolitan and Micropolitan. 2020. <https://www.census.gov/programs-surveys/metro-micro.html>.
 20. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the charlson comorbidity index with administrative data bases. *J Clin Epidemiol*. 1996;49(12):1429-1433.
 21. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol*. 2000;53(12):1258-1267. doi:10.1016/S0895-4356(00)00256-0
 22. Chen AB, Cronin A, Weeks JC, et al. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: A cancer care outcomes research and surveillance consortium (CanCORS) study. *J Clin Oncol*. 2013;31(5):558-564. doi:10.1200/JCO.2012.43.7954
 23. Murphy JD, Nelson LM, Chang DT, Mell LK, Le Q-T. *Patterns of Care in Palliative Radiotherapy: A Population-Based Study*; 2013.
 24. Stavas MJ, Arneson KO, Ning MS, et al. The refusal of palliative radiation in metastatic non-small cell lung cancer and its prognostic implications. *J Pain Symptom Manage*. 2015;49(6):1081-1087.e4. doi:10.1016/j.jpainsymman.2014.11.298
 25. Hayman JA, Abrahamse PH, Lakhani I, Earle CC, Katz SJ. Use of Palliative Radiotherapy Among Patients With Metastatic Non-Small-Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. 2007;69(4):1001-

1007. doi:10.1016/j.ijrobp.2007.04.059
26. Rosado Rivera M, Soto Torres F. Physician Attitudes on the Provision of Palliative Care in Puerto Rican Emergency Departments. <https://www.omicsonline.org/open-access/physician-attitudes-on-the-provision-of-palliative-care-in-puerto-rican-emergency-departments-2165-7386.10001201.pdf>. Published 2015. Accessed November 16, 2019.
 27. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. *J Clin Oncol*. 2004;22(16):3261-3268. doi:10.1200/JCO.2004.02.051
 28. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-medicare. *J Clin Oncol*. 2004;22(24):4971-4978. doi:10.1200/JCO.2004.05.031
 29. Wong J, Xu B, Yeung HN, et al. Age disparity in palliative radiation therapy among patients with advanced cancer. *Int J Radiat Oncol Biol Phys*. 2014;90(1):224-230. doi:10.1016/j.ijrobp.2014.03.050
 30. Fleming C, Rimner A, Foster A, Woo KM, Zhang Z, Wu AJ. Palliative efficacy and local control of conventional radiotherapy for lung metastases. *Ann Palliat Med*. 2017;6:S21-S27. doi:10.21037/apm.2017.03.08
 31. Plataniotis GA, Theofanopoulou MA, Sotiriadou K, Theodorou K, Mavroidis P, Kyrgias G. Palliative hypofractionated radiotherapy for non-small-cell lung cancer (NSCLC) patients previously treated by induction chemotherapy. *J Thorac Dis*. 2009;1(1):5-10.
 32. Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer. *Int J Radiat Oncol Biol Phys*. 2016;94(4):719-728. doi:10.1016/j.ijrobp.2015.12.012

Tables

Table 1: Baseline Characteristics and Univariate Predictors of Palliative RT Among Patients with NSCLC in Puerto Rico

		Palliative RT		
Characteristic	Total (%)	No n (row %)	Yes n (row %)	<i>P</i> value*
All patients	929 (100.0)	615 (66.20)	314 (33.80)	
Age group (years)				0.011*
21-59	258 (27.77)	155 (60.08)		
60-74	452 (48.65)	300 (66.37)	152 (33.63)	
75+	219 (23.57)	160 (73.06)	59 (26.94)	
Sex				0.732
Male	552 (59.42)	363 (65.76)	189 (34.24)	
Female	377 (40.58)	252 (66.84)	125 (33.16)	
Marital Status				0.596
Unmarried	396 (42.63)	269 (67.93)	127 (32.07)	
Married	508 (54.68)	329 (64.76)	179 (35.24)	
Unknown	25 (2.69)	17 (68.00)	8 (32.00)	
Health Insurance				<0.0001*
Medicaid	290 (31.22)	208 (71.72)	82 (28.28)	
Medicare	201 (21.64)	124 (61.69)	77 (38.31)	
Medicare-Medicaid	234 (25.19)	170 (77.65)	64 (27.35)	
Private	204 (21.96)	113 (55.39)	91 (44.61)	
Density of RT Centers				0.400
Low (0-2)	71 (7.64)	49 (69.01)	22 (30.99)	
Medium (3-6)	605 (65.12)	407 (67.27)	198 (32.73)	
High (7+)	253 (27.23)	159 (62.85)	94 (37.15)	
Geographic Location				0.163
Metro Area	894 (96.23)	588 (65.77)	306 (34.23)	
Non-Metro Area	35 (3.77)	27 (77.14)	8 (33.80)	
Surgery				0.249
No	847 (91.17)	556 (65.64)	291 (34.36)	

Yes	82 (8.83)	59 (71.95)	23 (28.05)	
Chemotherapy				<0.0001*
No	488 (52.53)	397 (81.35)	91 (18.65)	
Yes	441 (47.47)	218 (49.43)	223 (50.57)	
Year of Diagnosis				
2009	107 (11.52)	70 (65.42)	37 (34.58)	0.997
2010	85 (9.15)	55 (64.71)	30 (35.29)	
2011	121 (13.02)	82 (67.77)	39 (32.23)	
2012	151 (16.25)	102 (67.55)	49 (32.45)	
2013	156 (16.79)	101 (64.74)	55 (35.26)	
2014	148 (15.93)	99 (66.89)	49 (33.11)	
2015	161 (17.33)	106 (65.84)	55 (34.16)	
Symptoms				<0.0001*
No	319 (34.34)	239 (74.92)	80 (25.08)	
Yes	610 (65.66)	376 (64.64)	234 (38.36)	
Comorbidity				0.462
0	618 (66.52)	406 (65.70)	212 (34.30)	
1	153 (16.47)	98 (64.05)	55 (35.95)	
2+	158 (17.01)	111 (70.25)	47 (29.75)	

Abbreviation: NSCLC, non–small-cell lung cancer; RT, radiation therapy

* Pearson Chi Squared Test significant at $p < 0.05$

Table 2: Predictors of Palliative RT among Metastatic NSCLC Patients in Puerto Rico

Characteristic	Unadjusted Model		Adjusted Model	
	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
Age group (years)				
21-59	1.00	-	1.00	-
60-74	0.76 (0.56, 1.04)	0.093	0.80 (0.55, 1.16)	0.231
75+	0.55 (0.38, 0.82)	0.003	0.71 (0.44, 1.17)	0.182
Sex				
Male	1.00	-	1.00	-
Female	0.95 (0.72, 1.25)	0.732	0.87 (0.64, 1.19)	0.408
Marital Status				
Unmarried	1.00	-	1.00	-
Married	1.15 (0.87, 1.52)	0.318	0.91 (0.66, 1.26)	0.571
Unknown	0.99 (0.42, 2.37)	0.994	0.87 (0.34, 2.23)	0.779
Health Insurance				
Medicaid	1.00	-	1.00	-
Medicare	1.58 (1.07, 2.31)	0.020	1.47 (0.92, 2.37)	0.109
Medicare-Medicaid	0.95 (0.65, 1.40)	0.814	1.02 (0.64, 1.63)	0.920
Private	2.04 (1.40, 2.98)	<0.0001	1.50 (0.98, 2.29)	0.061
Density of RT Centers				
Low (0-2)	1.00	-	1.00	-
Medium (3-6)	1.08 (0.64, 1.84)	0.767	1.13 (0.62, 2.04)	0.685
High (7+)	1.32 (0.75, 2.31)	0.339	1.31 (0.70, 2.48)	0.394
Geographic Location				
Metro	1.00	-	1.00	-
Nonmetro	0.57	0.168	0.70 (0.29, 1.66)	0.416
Surgery				
No	1.00	-	1.00	-
Yes	0.74 (0.45, 1.23)	0.250	0.66 (0.39, 1.14)	0.137
Chemotherapy				

No	1.00	-	1.00	-
Yes	4.46 (3.32, 5.99)	<0.0001	3.90 (2.91, 5.45)	<0.0001
Year of Diagnosis				
2009	1.00		1.00	-
2010	1.03 (0.57, 1.87)	0.918	1.03 (0.54, 1.97)	0.932
2011	0.89 (0.52, 1.56)	0.707	0.98 (0.54, 1.79)	0.959
2012	0.91 (0.54, 1.54)	0.721	0.88 (0.50, 1.56)	0.659
2013	1.03 (0.61, 1.73)	0.910	0.96 (0.54, 1.68)	0.879
2014	0.94 (0.55, 1.58)	0.806	1.04 (0.59, 1.85)	0.870
2015	0.98 (0.58, 1.64)	0.944	1.19 (0.68, 2.10)	0.545
Symptoms				
No	1.00	-	1.00	-
Yes	1.86 (1.38, 2.51)	<0.0001	1.41 (1.00, 1.98)	0.045
Comorbidity				
0	1.00		1.00	-
1	1.07 (0.74, 1.55)	0.702	1.02 (0.68, 1.55)	0.919
2+	0.81 (0.55, 1.18)	0.279	0.86 (0.55, 1.33)	0.483

Abbreviations: CI, confidence interval; NSCLC, non–small-cell lung cancer; OR, odds ratio; RT, radiation therapy;

Figures

Figure 1

Cohort Selection